$-0.23
(Market cap
$2,578 Mln
Revenue (TTM)
$86 Mln
P/E Ratio
--
P/B Ratio
61.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-8.4 %
-
ROCE
-- %
-
Industry P/E
37.31
-
EV/EBITDA
-3.3
-
Debt to Equity
2.2
-
Book Value
$--
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
358,035,247
10 Years Aggregate
CFO
$-669.24 Mln
EBITDA
$-1,398.35 Mln
Net Profit
$-1,563.26 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Precigen (PGEN)
| 72.0 | 33.1 | 69.6 | 68.8 | 60.8 | 4.0 | -12.0 |
|
BSE Sensex
| -9.1 | 1.1 | 1.2 | -4.8 | 5.8 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Precigen (PGEN)
| 273.2 | -16.3 | -11.8 | -59.0 | -63.6 | 86.1 | -16.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Precigen (PGEN)
|
7.2 | 2,577.9 | 85.7 | -157.7 | -199.5 | -489.1 | -- | 61.1 |
| 18.0 | 6,238.0 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 188.9 | |
| 206.3 | 10,883.2 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 130.9 | |
| 78.7 | 15,932.7 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 116.9 | 13,215.0 | 830.8 | 54.9 | 3.2 | 8.1 | 271.7 | 18.7 | |
| 12.2 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 24.5 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 284.5 | 5,707.4 | 290.5 | 197.2 | 82.5 | 19.9 | 29.6 | 5.9 | |
| 69.9 | 6,142.1 | 450.9 | 138.6 | 39.1 | 115.6 | 49 | 31.5 | |
| 153.1 | 9,129.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 20.5 |
Shareholding Pattern
View DetailsAbout Precigen (PGEN)
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers... therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. Read more
-
Executive Chairman
Mr. Randal J. Kirk J.D.
-
Executive Chairman
Mr. Randal J. Kirk J.D.
-
Headquarters
Germantown, MD
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Precigen (PGEN)
What is the current share price of Precigen Inc (PGEN) Today?
The share price of Precigen Inc (PGEN) is $7.19 (NASDAQ) as of 27-Aug-2026 16:28 EDT. Precigen Inc (PGEN) has given a return of 60.78% in the last 3 years.
What is the current PB & PE ratio of Precigen Inc (PGEN)?
Since, TTM earnings of Precigen Inc (PGEN) is negative, P/E ratio is not available.
The P/B ratio of Precigen Inc (PGEN) is 61.13 times as on 21-Aug-2026, a 689 premium to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-5.22 |
62.56 |
2024 |
-2.60 |
8.52 |
2023 |
-3.48 |
2.81 |
2022 |
11.17 |
2.51 |
2021 |
-8.02 |
6.89 |
What is the 52 Week High and Low of Precigen Inc (PGEN)?
The 52-week high and low of Precigen Inc (PGEN) are Rs 7.72 and Rs 2.99 as of 28-Aug-2026.
What is the market cap of Precigen Inc (PGEN)?
Precigen Inc (PGEN) has a market capitalisation of $ 2,578 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Precigen Inc (PGEN)?
Before investing in Precigen Inc (PGEN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.